Clinical Trial Update: Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the efficacy, safety, and pharmacokinetics of CPL500036 in patients with levodopa-induced dyskinesia in Parkinson's disease and has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Levodopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• CPL500036

Snippet

Sponsor: Celon Pharma SA | Conditions: Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Status: COMPLETED